Rapid Micro Biosystems earnings missed by $0.03, revenue fell short of estimates
Rapid Micro Biosystems (RPID) reported Q3 EPS of -$0.23, missing estimates by $0.03, with revenue at $9.53M, below the $9.8M consensus. The stock closed at $0.65, down 61.02% over 3 months and 82.26% over 12 months. InvestingPro rates its financial health as 'fair performance'.
How this was made
The 30-second read
Why it matters
A simultaneous EPS and revenue miss typically pressures short-term sentiment and can lead to estimate cuts, especially for small-cap, loss-making issuers.
Market read
Traders can use the reported miss versus consensus to reassess near-term expectations and positioning around subsequent earnings.
What to watch
The article does not include guidance, cash burn, or backlog details, which could materially change the earnings quality assessment.
Background
The piece summarizes Rapid Micro Biosystems’ Q3 results versus analyst consensus and notes recent stock underperformance.
Ticker impact
Rapid Micro Biosystems reported Q3 EPS of -0.23, missing by 0.03, and revenue of $9.53M below the $9.8M consensus.
Likely downward pressure as the market digests the EPS and revenue shortfalls versus consensus.
The article provides the company’s own quarterly EPS and revenue versus consensus, which are direct drivers of post-earnings repricing.
Market effects
Limited read-through beyond biotech/life-science tools given the company-specific miss and microcap scale.
No clear regional spillover indicated; move is company-specific.
No global macro or cross-border catalyst mentioned.
Counterpoint
If the miss is driven by timing of revenue recognition rather than underlying demand, the stock could stabilize after initial repricing.
Key entities
- companyRapid Micro Biosystems
NASDAQ-listed company reporting Q3 EPS and revenue versus consensus.

